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1. Introduction 
We have shown that 2-mercaptoethanol administra- 
tion to the rat is followed by the induction of a fatty 
liver [ 1,2]. Among the different possible mechanisms 
responsible for this induction, increased peripheral 
fatty acid mobilization seems to play an important 
role [3,4], but is probably not the unique alteration 
involved in the pathogenesis of this type of fatty liver. 
In fact, ketogenesis from octanoate was found 
markedly reduced in liver homogenates from 2-mer- 
captoethanol treated rats, suggesting that, in addition 
to increased fatty acid input into the liver, inhibition 
of hepatic fatty oxidation may also occur in these 
animals [ 51. 
In [3,4] we have found that 2-mercaptoacetate 
administration also increased the rate of fatty acid 
mobilization and induced a fatty liver. Moreover, 
administration of pyrazole, an inhibitor of alcohol 
dehydrogenase [6], was shown to prevent the 2-mer- 
captoethanol -(but not the 2_mercaptoacetate-) in- 
duced fatty liver, suggesting that the toxic effects of 
2-mercaptoethanol could be due to 2-mercaptoacetate 
rather than to 2-mercaptoethanol per se [4]. 
The aim of this study was to determine whether 
2-mercaptoacetate may inhibit ketogenesis and, if so, 
whether such an inhibition could or not be related to 
a decreased rate of fatty acid oxidation in the liver. 
The present results show that 2-mercaptoacetate 
administration does, in fact, inhibit ketogenesis, an 
effect which is indeed related to &oxidation inhibi- 
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tion. Besides, 2-mercaptoacetate administration 
induces a dramatic enhancement of hepatic pyruvate 
level (> 15fold), the mechanism of the latter effect 
is discussed in relation to &oxidation inhibition, 
hepatic CoA-SH decrease or inhibition of pyruvate 
transport across the mitochondrial membrane. 
2. Materials and methods 
Female Wistar rats (200 f 20 g) were fasted over- 
night preceding the experiments. 2-Mercaptoacetate 
(40 pmol/lOO g body wt) was administered intra- 
peritoneally as in [3]; control rats received an equal 
volume of saline. Animals were sacrificed by decapi- 
tation 3 h later. For ketogenesis tudies, part of the 
liver was immediately excised and homogenized in 
ice-cold potassium phosphate buffer (0.1 M, pH 7.0). 
The final volume of homogenate (ml) was adjusted to 
3-times the weight of liver (g) then subjected to 1 
cycle of freeze thawing [7] before being used for the 
determination of the ketogenesis rate. 
Ketone body synthesis with octanoate or with 
acetyl-CoA as substrate was studied according to [7] 
with a slight modification (presence of NAD’ in the 
assay when ketogenesis from acetyl-CoA was studied). 
After a preincubation period of 2 min at 37°C the 
homogenates were added to the reaction mixtures 
containing the ketogenic substrate. When octanoate 
was the substrate, the final incubation mixture (3 ml) 
consisted of 0.1 M Tris-HCl buffer (pH 8.9, 5 mM 
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Table 1 
December 1979 
Ketone-body synthesis by liver homogenates from 2mercaptoacetate treated rats 
Animals Ketogenesis (acetoacetate t 3-hydroxybutyrate) (p mol g liver wet wtt’ h-r) from: 
Endogenous substrates Octanoate AcetylCoA 
Controls 
2-Mercaptoacetate 
treated 
78.2 i 5.9 (19) 24.5 f 7.0 (7) 57.0 f 13.5 (7) 
38.6 f 5.5 (16) 6.9 t 3.2 (8) 65.4 f 10.7 (6) 
p < 0.001 p < 0.001 p > 0.5 
Experimental conditions are described in section 2. Each value is the mean f SE, with no. determinations in 
parentheses 
MgCls ,5 mM ATP, 0.3 mM CoA-SH, 0.66 mM NAD’, 
0.5 ml homogenate and 3.3 mM octanoate. When 
acetyl-CoA was the substrate, the incubation mixture 
contained a generating system for acetyl-CoA con- 
sisting of 0.1 M Tris-HCl buffer (pH 8.5) 5 mM 
MgQ, 5 mM ATP, 1.5 mM CoA-SH, 30 units phospho- 
transacetylase, 0.66 mM NAD’, 0.5 ml homogenate 
and 27 mM acetylphosphate (final vol. 3 ml). Incu- 
bations were performed in parallel but in the absence 
of ketogenic substrates to determine the rate of ‘endog- 
enous ketogenesis’. After 4 min, the incubation 
mixtures were poured into centrifuge tubes containing 
0.3 ml ice-cold HC104 (70%, w/v). After neutraliza- 
tion, acetoacetate and 3-hydroxybutyrate were 
determined enzymatically according to [8]. 
In parallel with these determinations, liver CoA-SH 
[9] acetyl-CoA [lo], acyl-CoA [ 111 and pyruvate [ 121 
levels were determined according to the enzymatic 
methods cited. Blood glucose was also determined 
according to [ 131. Enzymes, coenzymes and substrates 
were from Sigma and 2-mercaptoacetate from Merck. 
3. Results 
As shown in table 1, ketogenesis from endogenous 
substrates was 50% reduced in liver homogenates 
from 2-mercaptoacetate-treated rats. This treatment 
also markedly altered the rate of ketone body synthe- 
sis from octanoate as substrate (75% inhibition). In 
contrast, with acetyl-CoA (acetylphosphate) as sub- 
strate, the net production of acetoacetate and 
3-hydroxybutyrate was not significantly modified by 
2-mercaptoacetate administration. These discrepant 
effects of 2-mercaptoacetate on ketogenesis from 
octanoate and acetylphosphate could be linked to the 
different concentrations of CoA-SH present in each 
of these experiments. However when ketogenesis 
from octanoate was determined under the same 
conditions as those used for the determination of 
ketogenesis from acetylphosphate (1.5 mM CoA-SH 
instead of 0.3 mM), the magnitude of the ketogen- 
esis inhibition was not altered (results not shown). 
As shown in table 2, 3 h after 2-mercaptoacetate 
Table 2 
Effects of 2-mercaptoacetate administration on liver CoA-SH, acetylCoA, acyl-CoA and pyruvate levels and on blood 
glucose in the rat 
Animals Liver concentrations (nmol/g wet wt) of: 
CoA-SH Acetyl-CoA AcylCoA CoA-SH + acetyl CoA 
+ acyl-CoA 
Pyruvate 
Blood 
glucose (mmol/l) 
Controls (6) 44 + 10 123 * 12 59+ 5 226 * 13 96 t 12 5.1 + 0.5 
2-Mercaptoacetate 9t 4 27+ 6 130 f 10 166 * 10 1481 f 18 3.0 ? 0.5 
treated (6) 
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 0.001 < p < 0.01 
Experimental conditions are described in section 2. Each value is the mean * SE., with no. determinations in parentheses 
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administration, the hepatic levels of free CoA-SH 
and acetyl-CoA were markedly decreased, falling to 
-20% of the control values. At the same time, on the 
contrary, the hepatic acyl-CoA level was increased 
(+ 120%), an effect which did not completely balance, 
however, the reduction in free CoA-SH and acetyl- 
CoA concentrations. Moreover, 2-mercaptoacetate 
treatment induced both a dramatic increase (> 15- 
fold) of the hepatic pyruvate level and a significant 
reduction (-40%) of the blood glucose level (table 2). 
4. Discussion 
We show that 2-mercaptoacetate administration 
induces an increase in liver acyl-CoA, a decrease in 
liver acetyl-CoA and a reduction of the rate of keto- 
genesis from octanoate, but not from acetyl-CoA. 
It can thus be assumed that these effects are all related 
to an inhibition of the P-oxidation pathway. This can 
be due either to a decrease in the availability of acyl- 
CoA in the mitochondria or, as shown in the case of 
4-pentenoate administration [14-l 61, to a selective 
and direct inhibition of one or more of the enzymes 
involved in this pathway (acyl-CoA dehydrogenase, 
enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydro- 
genase or 3-ketoacyl-CoA thiolase, but not acetoace- 
tyl-CoA thiolase since this enzyme is also involved in 
ketogenesis from acetyl-CoA, a pathway which is 
unaltered by 2-mercaptoacetate). Although the 
intramitochondrial acyl-CoA level was not specifically 
assessed in these experiments, the marked increase 
in hepatic acyl-CoA level found in the 2-mercapto- 
acetate treated rats would suggest hat the acyl-CoA 
availability for /3-oxidation is not reduced in the liver 
of these animals. Therefore, the most probable 
mechanism concerned in the 2-mercaptoacetate-in- 
duced P-oxidation inhibition appears to be the inhi- 
bition of one or more of the enzymes involved in 
this pathway. 
From these experiments it is clear that hepatic 
disturbances other than those affecting P-oxidation 
(but which could be related at least in part to inhibi- 
tion of this pathway) also occur after 2-mercapto- 
acetate administration. In fact, it has been shown 
that, in these fasted rats, the hepatic pyruvate level 
was considerably increased, an effect which could 
result from a direct and/or an indirect inhibition of 
the mitochondrial utilization of pyruvate by 2-mer- 
captoacetate. 
(9 
(ii) 
The latter compound may indeed directly impede 
the mitochondrial metabolism of pyruvate by 
combining with the thiol group which belongs to 
the carrier involved in pyruvate transport across 
the mitochondrial membrane [ 171. 
As 2-mercaptoacetate inhibits @oxidation, this 
compound may also indirectly interfere with the 
mitochondrial utilization of pyruvate: in fact, 
pyruvate carboxylase activity, which is elevated 
in these animals because of their fasting status 
[ 181, should be reduced as a consequence of the 
drop in acetyl-CoA level [ 191. Besides, evidence 
in favour of the inhibition of this neoglucogenic 
enzyme is provided by the hypoglycaemia 
observed in the treated animals. 
(iii) The marked decrease in free CoA-SH availability 
observed in the liver of 2-mercaptoacetate 
treated rats would also contribute to reduce 
the rate of pyruvate utilization by the mitochon- 
dria as it is a factor known to induce deinhibi- 
tion of pyruvate dehydrogenase kinase [20]. 
Considering now the results in table 2, it is obvious 
that the fall in the free CoA-SH + acetyl-CoA levels 
found in the liver after 2-mercaptoacetate treatment 
is only partly balanced by the concomitant increase 
in the acyl-CoA concentration due to P-oxidation 
inhibition. This indicates that, in the treated-animals, 
part of the free CoA-SH (- 60 nmol/g wet wt) has 
become unavailable for acylation reactions. Among 
the different mechanisms which could be evoked to 
explain such a gap, it is tempting to speculate upon a 
possible competition of 2-mercaptoacetate with ace- 
tate, a competition which should lead to mercapto- 
acetyl-CoA instead of acetyl-CoA. Regardless on 
the mechanism of this reduction of the free CoA-SH 
level, it appears likely that such a reduction plays also 
an important role in the inhibitory effect of 
2-mercaptoacetate on P-oxidation. A reduction of the 
intramitochondrial CoA-SH pool would indeed reduce 
the activity of the mitochondrial fatty acid thiokinase 
and, as suggested in heart mitochondria [21], of 
3-ketoacyl-CoA thiolase. 
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